

**HPTN 094 – INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care**  
**LIVE Open Report – September 15, 2025**  
**Visit Cutoff Date: September 15, 2025**  
**Table O4a – Disposition Summary by Site: HIV+**

	<b>Overall</b>	<b>New York – Bronx Prevention</b>	<b>Los Angeles – Vine Street</b>	<b>Washington DC – Washington Circle</b>	<b>Houston AIDS Research Team CRS</b>	<b>Philadelphia</b>
Total Participants Enrolled	38	12	2	6	7	11
Still in Follow-up	0/38 (0.0%)	0/12 (0.0%)	0/2 (0.0%)	0/6 (0.0%)	0/7 (0.0%)	0/11 (0.0%)
Terminated Early	9/38 (23.7%)	5/12 (41.7%)	0/2 (0.0%)	1/6 (16.7%)	2/7 (28.6%)	1/11 (9.1%)
Death	2/9 (22.2%)	1/5 (20.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	1/1 (100.0%)
Participant refused further participation	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Lost to follow-up	4/9 (44.4%)	3/5 (60.0%)	0/0 (-%)	1/1 (100.0%)	0/2 (0.0%)	0/1 (0.0%)
Investigator decision	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Early study closure	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Protocol deviation	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Serious adverse event	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Withdrawal of consent by participant	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Study terminated by sponsor	0/9 (0.0%)	0/5 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/2 (0.0%)	0/1 (0.0%)
Other	3/9 (33.3%)	1/5 (20.0%)	0/0 (-%)	0/1 (0.0%)	2/2 (100.0%)	0/1 (0.0%)
Completed Study	29/38 (76.3%)	7/12 (58.3%)	2/2 (100.0%)	5/6 (83.3%)	5/7 (71.4%)	10/11 (90.9%)

**HPTN 094 – INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care**  
**LIVE Open Report – September 15, 2025**  
**Visit Cutoff Date: September 15, 2025**  
**Table O4b – Disposition Summary by Site: HIV–**

	<b>Overall</b>	<b>New York – Bronx Prevention</b>	<b>Los Angeles – Vine Street</b>	<b>Washington DC – Washington Circle</b>	<b>Houston AIDS Research Team CRS</b>	<b>Philadelphia</b>
Total Participants Enrolled	409	82	93	35	97	102
Still in Follow-up	0/409 (0.0%)	0/82 (0.0%)	0/93 (0.0%)	0/35 (0.0%)	0/97 (0.0%)	0/102 (0.0%)
Terminated Early	92/409 (22.5%)	31/82 (37.8%)	15/93 (16.1%)	8/35 (22.9%)	24/97 (24.7%)	14/102 (13.7%)
Death	17/92 (18.5%)	3/31 (9.7%)	5/15 (33.3%)	1/8 (12.5%)	4/24 (16.7%)	4/14 (28.6%)
Participant refused further participation	1/92 (1.1%)	1/31 (3.2%)	0/15 (0.0%)	0/8 (0.0%)	0/24 (0.0%)	0/14 (0.0%)
Lost to follow-up	62/92 (67.4%)	27/31 (87.1%)	10/15 (66.7%)	7/8 (87.5%)	15/24 (62.5%)	3/14 (21.4%)
Investigator decision	0/92 (0.0%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/24 (0.0%)	0/14 (0.0%)
Early study closure	0/92 (0.0%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/24 (0.0%)	0/14 (0.0%)
Protocol deviation	0/92 (0.0%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/24 (0.0%)	0/14 (0.0%)
Serious adverse event	0/92 (0.0%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/24 (0.0%)	0/14 (0.0%)
Withdrawal of consent by participant	1/92 (1.1%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	1/24 (4.2%)	0/14 (0.0%)
Study terminated by sponsor	0/92 (0.0%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/24 (0.0%)	0/14 (0.0%)
Other	11/92 (12.0%)	0/31 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	4/24 (16.7%)	7/14 (50.0%)
Completed Study	317/409 (77.5%)	51/82 (62.2%)	78/93 (83.9%)	27/35 (77.1%)	73/97 (75.3%)	88/102 (86.3%)

**HPTN 094 – INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care**  
**LIVE Open Report – September 15, 2025**  
**Visit Cutoff Date: September 15, 2025**  
**Table O4c – Disposition Summary by HIV Status**

	<b>Overall</b>	<b>HIV+</b>	<b>HIV-</b>
Total Participants Enrolled	447	38	409
Still in Follow-up	0/447 (0.0%)	0/38 (0.0%)	0/409 (0.0%)
Terminated Early	101/447 (22.6%)	9/38 (23.7%)	92/409 (22.5%)
Death	19/101 (18.8%)	2/9 (22.2%)	17/92 (18.5%)
Participant refused further participation	1/101 (1.0%)	0/9 (0.0%)	1/92 (1.1%)
Lost to follow-up	66/101 (65.3%)	4/9 (44.4%)	62/92 (67.4%)
Investigator decision	0/101 (0.0%)	0/9 (0.0%)	0/92 (0.0%)
Early study closure	0/101 (0.0%)	0/9 (0.0%)	0/92 (0.0%)
Protocol deviation	0/101 (0.0%)	0/9 (0.0%)	0/92 (0.0%)
Serious adverse event	0/101 (0.0%)	0/9 (0.0%)	0/92 (0.0%)
Withdrawal of consent by participant	1/101 (1.0%)	0/9 (0.0%)	1/92 (1.1%)
Study terminated by sponsor	0/101 (0.0%)	0/9 (0.0%)	0/92 (0.0%)
Other	14/101 (13.9%)	3/9 (33.3%)	11/92 (12.0%)
Completed Study	346/447 (77.4%)	29/38 (76.3%)	317/409 (77.5%)